Skip to main content
SpringerLink
Log in

Authors’ Reply to Garattini and Freemantle: “Value-Based Pricing Alternatives for Personalised Drugs: Implications of Asymmetric Information and Competition”

  • Letter to the Editor
  • Published:
Applied Health Economics and Health Policy Aims and scope Submit manuscript

A Current Opinion to this article was published on 02 December 2019

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Garattini L, Freemantle N. Comment on: “value-based pricing alternatives for personalised drugs: implications of asymmetric information and competition”. Appl Health Econ Health Policy. 2020.

  2. Levaggi R, Pertile P. Value-based pricing alternatives for personalised drugs: implications of asymmetric information and competition. Appl Health Econ Health Policy. 2019. https://doi.org/10.1007/s40258-019-00541-z.

    Article  Google Scholar 

  3. Lakdawalla DN. Economics of the Pharmaceutical Industry. J Econ Lit. 2018;56:397–449.

    Article  Google Scholar 

  4. World Health Organization. Pricing cancer medicine and its impacts. World Health Organzation; 2018.

  5. Vogler S, Paris V, Ferrario A, Wirtz VJ, de Joncheere K, Schneider P, et al. How can pricing and reimbursement policies improve affordable access to medicines? Lessons learned from European countries. Appl Health Econ Health Policy. 2017;15:307–21.

    Article  Google Scholar 

  6. Garattini L, Padula A. Pharmaceutical pricing conundrum: time to get rid of it? Eur J Health Econ. 2018;19:1035–8.

    Article  Google Scholar 

  7. Katz A. Pharmaceutical lemons: innovation and regulation in the drug industry. Mich Telecommun Technol Law Rev. 2007;14:1–41.

    Google Scholar 

  8. Prasad V, Mailankody S. Research and development spending to bring a single cancer drug to market and revenues after approval. JAMA Intern Med. 2017;177:1569–75.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Economics and Management, University of Brescia, Via San Faustino 74b, 25122, Brescia, Italy

    Rosella Levaggi

  2. Department of Economics, University of Verona, Via Cantarane, 24, 37129, Verona, Italy

    Paolo Pertile

Authors
  1. Rosella Levaggi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Paolo Pertile
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rosella Levaggi.

Ethics declarations

Funding

The authors have not receive any specific funding for the research.

Conflict of interest

The authors have no conflict of interest to declare.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Levaggi, R., Pertile, P. Authors’ Reply to Garattini and Freemantle: “Value-Based Pricing Alternatives for Personalised Drugs: Implications of Asymmetric Information and Competition”. Appl Health Econ Health Policy 18, 455–456 (2020). https://doi.org/10.1007/s40258-020-00557-w

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40258-020-00557-w

Search

Navigation